A Study of RNDO-564 Alone and in Combination With Pembrolizumab in People With Bladder Cancer and Other Types of Solid Tumor Cancer

Full Title

An Open-Label, Multicenter, Phase 1/1b Study of RNDO-564 as Monotherapy and in Combination with Pembrolizumab in Adult Participants with Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer and Other Solid Tumors Associated with Nectin-4 Expression

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Aditi Gupta’s office at 646-422-4425.